Literature DB >> 4073881

Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods.

L B Heifets, M D Iseman, P J Lindholm-Levy, W Kanes.   

Abstract

A radiometric method to determine the MIC of ansamycin (LM427) for Mycobacterium avium complex clinical isolates has been developed. It is based on a comparison of the conventional growth curve determination and the radiometric detection of growth (growth index) in the same liquid medium (7H12 broth). This new method requires less time and labor than does a conventional determination of MIC in liquid medium (CFU). Other advantages of this method include relatively short periods of exposure of the drug to 37 degrees C and the composition of 7H12 broth, which has practically no substrates which could absorb or bind the drug. Thus, a more accurate estimation of the MIC in this medium can be expected than by the conventional agar dilution (proportion) method. The MICs of ansamycin appeared to be higher in agar plates than in 7H12 broth. More than 70% of the isolates had a broth-determined MIC one to three times lower than the average peak concentration of ansamycin achieved in sera of patients. The wide range of MICs suggests the importance of testing susceptibility in broth with many concentrations in addition to, or rather than in, agar plates with concentrations of 2.0 or 1.0 micrograms/ml only. Taking into account relatively low levels of ansamycin in sera of patients, it would be appropriate to compare the MICs with the levels in serum to make the outcome of chemotherapy more predictable.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4073881      PMCID: PMC180307          DOI: 10.1128/AAC.28.4.570

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Infections with atypical mycobacteria. Five years' experience at the National Jewish Hospital.

Authors:  D A Fischer; W Lester; W B Schaefer
Journal:  Am Rev Respir Dis       Date:  1968-07

2.  Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  S H Siddiqi; J P Libonati; G Middlebrook
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

3.  Assay of rifampicin in serum.

Authors:  J M Dickinson; V R Aber; B W Allen; G A Ellard; D A Mitchison
Journal:  J Clin Pathol       Date:  1974-06       Impact factor: 3.411

4.  The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.

Authors:  P D Ellner; H C Neu
Journal:  JAMA       Date:  1981-10-02       Impact factor: 56.272

5.  [Comparative study of the development of rifomycin blood levels in humans by 2 different microbiologic methods].

Authors:  G Canetti; V Djurovic; M Le Lirzin; R Thibier; A Lepeuple
Journal:  Rev Tuberc Pneumol (Paris)       Date:  1970

6.  Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media.

Authors:  G Middlebrook; Z Reggiardo; W D Tigertt
Journal:  Am Rev Respir Dis       Date:  1977-06

7.  Biological activity of a new class of rifamycins. Spiro-piperidyl-rifamycins.

Authors:  A Sanfilippo; C Della Bruna; L Marsili; E Morvillo; C R Pasqualucci; G Schioppacassi; D Ungheri
Journal:  J Antibiot (Tokyo)       Date:  1980-10       Impact factor: 2.649

8.  Treatment of disease due to Mycobacterium intracellulare.

Authors:  P T Davidson; V Khanijo; M Goble; T S Moulding
Journal:  Rev Infect Dis       Date:  1981 Sep-Oct

9.  MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.

Authors:  G CANETTI; S FROMAN; J GROSSET; P HAUDUROY; M LANGEROVA; H T MAHLER; G MEISSNER; D A MITCHISON; L SULA
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

10.  Rapid drug-susceptibility testing of Mycobacterium tuberculosis.

Authors:  D E Snider; R C Good; J O Kilburn; L F Laskowski; R H Lusk; J J Marr; Z Reggiardo; G Middlebrook
Journal:  Am Rev Respir Dis       Date:  1981-04
View more
  24 in total

1.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

Authors:  U Hjelm; J Kaustová; M Kubín; S E Hoffner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

Review 3.  Antimycobacterial susceptibility testing: present practices and future trends.

Authors:  C B Inderlied
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

4.  Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

Authors:  R Hafner; J Bethel; M Power; B Landry; M Banach; L Mole; H C Standiford; S Follansbee; P Kumar; R Raasch; D Cohn; D Mushatt; G Drusano
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex.

Authors:  R C Li; S Nightingale; R C Lewis; D C Colborn; P K Narang
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages.

Authors:  N Mor; B Simon; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

7.  Nontubercular Mycobacteria in drinking water of some educational institutes in Jabalpur (M.P.), India.

Authors:  Anjana Sharma; Sachin Kumar Chandraker; Manisha Bharti
Journal:  Indian J Microbiol       Date:  2007-10-04       Impact factor: 2.461

8.  Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex.

Authors:  S P Klemens; M A Grossi; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits.

Authors:  M Emori; H Saito; K Sato; H Tomioka; T Setogawa; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

10.  Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium.

Authors:  N Mor; J Vanderkolk; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.